Quality of Life Assessment After Concurrent Chemoradiation for Invasive Bladder Cancer: Results of a Multicenter Prospective Study (GETUG 97-015)

Lagrange, Jean‐Léon; Bascoul-Mollevi, Caroline; Geoffrois, Lionnel; Beckendorf, V.; Ferrero, Jean-­Marc; Joly, Florence; Allouache, N.; Bachaud, Jean-Marc; Chevreau, Christine; Kramar, Andrew; Chauvet, B.

doi:10.1016/j.ijrobp.2009.10.038

Cited by 88 publications

(43 citation statements)

References 22 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several larger phases II-III studies of chemo-radiation therapy series compare favorably to results reported by primary cystectomy (with or without adjuvant therapy) with 60% to 70% of complete response after chemo-radiation [1][2][3][4] and 3-year overall survival at 40%-50% [2,4,5,6]. Further 75% of the patients achieved cure with maintained bladder function [7,8].…”

Section: Introductionmentioning

confidence: 78%

Bladder-Preservation Therapy in Muscle-Invasive Bladder Cancer: A Single Centre Experience

Bourhafour¹,

Elallam²,

Elalami³

et al. 2016

IOSR

View full text Add to dashboard Cite

(6%), 21 (46%), 7 (15%) and 15 (33%) for T1, T2, T3 and T4, respectively. Treatment consisted in a transurethral resection of bladder tumor as complete as feasible followed by curative concurrent chemoradiation. Results:Twenty-nine patients showed complete response (CR), 22 of whom (48%) had a continuously tumor free bladder. With a median follow-up of 30 months (12-92 months), the 3-year overall survival (OS) was 50%; Local recurrence-free survival (LRFS) was 59% at 3 years and the distant metastases free survival (MFS) was

show abstract

Section: Introductionmentioning

confidence: 78%

Bladder-Preservation Therapy in Muscle-Invasive Bladder Cancer: A Single Centre Experience

Bourhafour¹,

Elallam²,

Elalami³

et al. 2016

IOSR

View full text Add to dashboard Cite

show abstract

“…However, it is difficult to compare data on trimodality therapy and radical cystectomy secondary to study variations in patient populations and selection biases. For instance, whether or not a patient is fit for surgery has been shown to be a predictor of overall survival among patient undergoing trimodality therapy [51,52]. Furthermore, contemporary radical cystectomy outcomes incorporating the increased utilization of neoadjuvant chemotherapy and the potential benefits of extended node dissection, may be distinct from the longterm, single-center retrospective studies that have been published, and thus using historical series to compare present day treatment options may prove inaccurate.…”

Section: Discussionmentioning

confidence: 99%

Bladder preservation in the treatment of muscle-invasive bladder cancer

Prado

Gollapudi

King

et al. 2014

Bladder

View full text Add to dashboard Cite

Organ preserving strategies are being increasingly utilized in the treatment of solid malignancies with the intent of reducing surgical morbidity and maintaining quality of life. Organ preservation becomes a viable approach only when cancer outcomes are not compromised when compared to radical resection. We reviewed the current literature on bladder preservation for muscle-invasive bladder cancer, focusing on trimodality therapy consisting of complete transurethral resection, radiation therapy, and chemotherapy. Acknowledging the absence of randomized clinical trials, differences in patient selection, and variation in study protocols, trimodality therapy may yield similar 5-and 10-year overall survival rates compared to radical cystectomy alone. This includes the approximately 30% of patients who enter a bladder preservation protocol and undergo salvage radical cystectomy for failure of local control. Currently, bladder preservation appears to be an alternative to radical cystectomy in select patients who have appropriate rigorous surveillance.

show abstract

“…La bonne tolérance de la chimioradiothérapie concomitante a par ailleurs été confirmée dans l'essai prospectif multicentrique 97-015 du groupe d'étude des tumeurs urogénitales (Gétug) évaluant la qualité de vie qui était maintenue chez plus de 70 % des patients sans signes de récidive à 36 mois. La chimioradiothérapie concomitante était également à l'origine d'une amélioration de la fonction vési-cale après traitement et d'une préservation de la fonction sexuelle chez 79 % des patients à 18 mois [36]. À long terme, ces résultats semblent se maintenir.…”

Section: Rationnel De La Chimioradiothérapie Des Tumeurs Infiltrantesunclassified

Chimioradiothérapie concomitante des tumeurs infiltrantes de la vessie : acquis, controverses et perspectives

Bellefqih

Khalil

Mezouri

et al. 2014

Cancer/Radiothérapie

View full text Add to dashboard Cite

Quality of Life Assessment After Concurrent Chemoradiation for Invasive Bladder Cancer: Results of a Multicenter Prospective Study (GETUG 97-015)

Cited by 88 publications

References 22 publications

Bladder-Preservation Therapy in Muscle-Invasive Bladder Cancer: A Single Centre Experience

Bladder-Preservation Therapy in Muscle-Invasive Bladder Cancer: A Single Centre Experience

Bladder preservation in the treatment of muscle-invasive bladder cancer

Chimioradiothérapie concomitante des tumeurs infiltrantes de la vessie : acquis, controverses et perspectives

Contact Info

Product

Resources

About